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antibiotics were higher (p = 0.004) in PCT compared to control group. A post hoc analysis including
all PCT values in the intention-to-treat population demonstrated a significant increase on the first day
of infection in patients with pneumonia and sepsis compared to patients with urinary tract infections
or without infections (p < 0.0001). CONCLUSION PCTus-guided antibiotic therapy did not improve
functional outcome at 3 months after severe ischemic stroke. PCT is a promising biomarker for early
detection of pneumonia and sepsis in acute stroke patients.
DOI: https://doi.org/10.3389/fneur.2017.00153
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-142954
Veröffentlichte Version
 
 
Originally published at:
Ulm, Lena; Hoffmann, Sarah; Nabavi, Darius; Hermans, Marcella; Mackert, Bruno-Marcel; Hamilton,
Frank; Schmehl, Ingo; Jungehuelsing, Gerhard-Jan; Montaner, Joan; Bustamante, Alejandro; Katan,
Mira; Hartmann, Andreas; Ebmeyer, Stefan; Dinter, Christiane; Wiemer, Jan C; Hertel, Sabine; Meisel,
Christian; Anker, Stefan D; Meisel, Andreas (2017). The Randomized Controlled STRAWINSKI Trial:
Procalcitonin-Guided Antibiotic Therapy after Stroke. Frontiers in Neurology, 8:153.
DOI: https://doi.org/10.3389/fneur.2017.00153
2
April 2017 | Volume 8 | Article 1531
CliniCal Trial
published: 24 April 2017
doi: 10.3389/fneur.2017.00153
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Guillaume Turc, 
Centre hospitalier 
Sainte-Anne, France
Reviewed by: 
David J. Seiffge, 
University of Basel, Switzerland 
Konstantinos Tziomalos, 
Aristotle University of 
Thessaloniki, Greece
*Correspondence:
Andreas Meisel 
andreas.meisel@charite.de
Specialty section: 
This article was 
submitted to Stroke, 
 a section of the journal 
Frontiers in Neurology
Received: 08 March 2017
Accepted: 03 April 2017
Published: 24 April 2017
Citation: 
Ulm L, Hoffmann S, Nabavi D, 
Hermans M, Mackert B-M, 
Hamilton F, Schmehl I, 
Jungehuelsing G-J, Montaner J, 
Bustamante A, Katan M, 
Hartmann A, Ebmeyer S, Dinter C, 
Wiemer JC, Hertel S, Meisel C, 
Anker SD and Meisel A (2017) The 
Randomized Controlled STRAWINSKI 
Trial: Procalcitonin-Guided Antibiotic 
Therapy after Stroke. 
Front. Neurol. 8:153. 
doi: 10.3389/fneur.2017.00153
The randomized Controlled 
STraWinSKi Trial: Procalcitonin-
Guided antibiotic Therapy 
after Stroke
Lena Ulm1,2,3, Sarah Hoffmann1,3, Darius Nabavi4, Marcella Hermans4,  
Bruno-Marcel Mackert5, Frank Hamilton5, Ingo Schmehl6, Gerhard-Jan Jungehuelsing3,7, 
Joan Montaner 8, Alejandro Bustamante8, Mira Katan9, Andreas Hartmann10,  
Stefan Ebmeyer11, Christiane Dinter11, Jan C. Wiemer11, Sabine Hertel11,  
Christian Meisel12, Stefan D. Anker13,14 and Andreas Meisel1,3*
1 NeuroCure Clinical Research Center, Charité – Universitaetsmedizin Berlin, Berlin, Germany, 2 Centre for Clinical Research, 
The University of Queensland, Brisbane, QLD, Australia, 3Department of Neurology and Center for Stroke Research Berlin, 
Charité – Universitaetsmedizin Berlin, Berlin, Germany, 4 Department of Neurology, Vivantes Klinikum Neukoelln, Berlin, 
Germany, 5 Department of Neurology, Vivantes Auguste-Viktoria-Klinikum, Berlin, Germany, 6 Department of Neurology, 
Unfallkrankenhaus Berlin, Berlin, Germany, 7 Department of Neurology, Juedisches Krankenhaus Berlin, Berlin, Germany, 
8 Neurovascular Research Laboratory, Institut de Recerca, Hospital Universitari Vall d’Hebrón, Universitat Autònoma de 
Barcelona, Barcelona, Spain, 9Department of Neurology, Universitaetsspital Zuerich, Zurich, Switzerland, 10 Department  
of Neurology, Klinikum Frankfurt Oder, Frankfurt Oder, Germany, 11 Thermo Fisher Scientific BRAHMS GmbH, Hennigsdorf, 
Germany, 12 Department of Immunology, Charité – Universitaetsmedizin Berlin, Berlin, Germany, 13 Division of Innovative 
Clinical Trials, Department of Cardiology and Pneumology, University Medical Centre Goettingen, Goettingen, Germany, 
14 Centre for Clinical and Basic Research, IRCCS, Rome, Italy
Background: Pneumonia is among the most common acute complications after stroke 
and is associated with poor long-term outcome. Biomarkers may help identifying stroke 
patients at high risk for developing stroke-associated pneumonia (SAP) and to guide 
early treatment.
aims: This trial investigated whether procalcitonin (PCT) ultrasensitive (PCTus)-guided 
antibiotic treatment of SAP can improve functional outcome after stroke.
Methods: In this international, multicenter, randomized, controlled clinical trial with 
blinded assessment of outcomes, patients with severe ischemic stroke in the middle 
cerebral artery territory were randomly assigned within 40  h after symptom onset to 
PCTus-based antibiotic therapy guidance in addition to stroke unit care or standard 
stroke unit care alone. The primary endpoint was functional outcome at 3  months, 
defined according to the modified Rankin Scale (mRS) and dichotomized as acceptable 
(≤4) or unacceptable (≥5). Secondary endpoints included usage of antibiotics, infection 
rates, days of fever, and mortality. The trial was registered with http://ClinicalTrials.gov 
(Identifier NCT01264549).
results: In the intention-to-treat-analysis based on 227 patients (112 in PCT and 
115 in control group), 197 patients completed the 3-month follow-up. Adherence to 
PCT guidance was 65%. PCT-guided therapy did not improve functional outcome as 
measured by mRS (odds ratio 0.79; 95% confidence interval 0.45–1.35, p =  0.47). 
Pneumonia rate and mortality were similar in both groups. Days with fever tended to 
be lower (p = 0.055), whereas total number of days treated with antibiotics were higher 
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(p = 0.004) in PCT compared to control group. A post hoc analysis including all PCT 
values in the intention-to-treat population demonstrated a significant increase on the first 
day of infection in patients with pneumonia and sepsis compared to patients with urinary 
tract infections or without infections (p < 0.0001).
Conclusion: PCTus-guided antibiotic therapy did not improve functional outcome at 
3 months after severe ischemic stroke. PCT is a promising biomarker for early detection 
of pneumonia and sepsis in acute stroke patients.
Keywords: stroke, pneumonia, antibiotic prophylaxis, procalcitonin, outcome, infections, biomarker-guided 
treatment
inTrODUCTiOn
Infections are among the most common acute complications after 
stroke and associated with poor outcome (1, 2). Prophylactic 
antimicrobial treatment effectively reduced infection rates in 
experimental models of stroke (3) and clinical proof-of-concept 
studies [for a meta-analysis, see the study by Westendorp et al. (4)]. 
However, the impact of preventive antibiotic treatment on long-
term functional outcome remained unclear, as previous clinical 
trials were not sufficiently powered to address this issue. Recently, 
two large randomized controlled phase III clinical trials demon-
strated that antibiotics commonly used to treat stroke-associated 
pneumonia (SAP) neither reduce the frequency of pneumonia 
nor improve the outcome after stroke when administered in a 
prophylactic manner (5–7).
Current European and US stroke guidelines strictly recom-
mend early antibiotic treatment of poststroke infections but 
advise against their prophylactic use (8). Biomarkers might help 
to identify patients in the early subclinical course of SAP or 
even at high risk for developing SAP, thereby tailoring antibiotic 
treatment to patients with the highest probability to benefit while 
reducing the risk of antibiotic resistances (9). Procalcitonin 
(PCT), an early marker of severe bacterial infections (10), has been 
useful in diagnosing SAP in previous observational clinical studies 
(11, 12). In addition, PCT guidance has been shown to reduce the 
duration of antibiotic treatment in critically ill patients, without 
compromising patients’ safety. In this study, we investigated 
whether PCT ultrasensitive (PCTus)-guided antibiotic treatment 
improves functional outcome after severe stroke by early identifi-
cation and treatment of pneumonia.
METHODS
Study Design and Participants
Patients from 10 study centers were randomly assigned in a 1:1 
ratio to standard stroke unit care plus PCTus-guided antibiotic 
treatment or to standard stroke unit care alone. Study procedures 
have been described in detail elsewhere (13). Inclusion criteria 
were age ≥18 years, severe ischemic stroke (score of >9 on the 
National Institute of Health Stroke Scale), and clinical diagnosis 
of a stroke in the middle cerebral artery (MCA) territory. In the 
initial study protocol, enrollment was planned within 36 h after 
symptom onset. As this time window turned out to be logisti-
cally difficult for the PCT measurements, we amended the study 
protocol and changed it to <40 h after symptom onset. Exclusion 
criteria included CT/MRI evidence of intracerebral hemorrhage 
or lacunar infarction, use of antibiotics within the last 10 days, 
suspected life expectancy of <3  months (irrespective of the 
underlying cause), modified Rankin Scale (mRS) before stroke 
onset ≥4, participation in other interventional trials (pharmaceu-
ticals or medical devices), and pregnancy/lactation.
Standard Protocol approvals, 
registrations, and Patient Consents
The trial was registered with http://ClinicalTrials.gov (Identifier 
NCT01264549). Patients’ safety was ensured by daily clinical 
monitoring throughout the intervention period, as well as severe 
adverse event (SAE) documentation, and supervision by a Data 
Safety Monitoring Board (13).
randomization and Masking
Creation of randomization lists and treatment allocations were 
described previously (13). Local investigators were not masked, 
but patients and assessors of outcome were masked to which 
group the patients were assigned to. Outcome after 3 months was 
centrally assessed by structured telephone interviews conducted 
by trained staff members in the study center. Outcomes after 
6  months were assessed by personal anamnesis and medical 
records. If these were not available, telephone interviews were 
conducted as for the 3-month outcome assessment. Where recon-
tacting was not successful, an enquiry was sent to the registration 
office where possible to establish if the patients were still alive.
intervention
Control Group
Patients were treated according to the current standards of 
therapy. With respect to antibiotics, they were fully and effectively 
treated as soon as an antibiotic medication was indicated, i.e., as 
soon as an infection was diagnosed by the treating physician 
based on current guidelines (8).
PCT Group
PCT ultrasensitive was assessed at study inclusion and every 
morning during routine clinical evaluation for 7 days. In patients 
with PCTus concentration ≤0.05 ng/ml, a bacterial infection was 
considered unlikely, and the use of antibiotics was discouraged. 
In patients with a PCTus concentration >0.05 ng/ml, a bacterial 
infection was considered likely, and the use of antibiotics was 
FiGUrE 1 | Trial profile.
3
Ulm et al. PCT-Guided Antibiotic Therapy in Stroke
Frontiers in Neurology | www.frontiersin.org April 2017 | Volume 8 | Article 153
recommended. As in the control group, type and duration of 
antibiotic treatment were left to the discretion of the treating 
physician. The rationale for choosing a cutoff value of 0.05 ng/ml 
has been described previously (13).
Outcomes
The primary endpoint was functional outcome 3  months after 
stroke onset measured by mRS, dichotomized as acceptable 
outcome (≤4) or unacceptable outcome (≥ 5) (13). In line with 
previous trials that included patients with severe MCA strokes 
(14), this dichotomization was chosen because survival without 
or with only mild disability following severe MCA infarction is 
rare. The primary aim of this study was to investigate whether 
PCTus-guided antibiotic treatment reduces mortality without 
increasing the number of severely disabled survivors (mRS score 
of 5). Secondary endpoints included time to first event of death 
or rehospitalization; mortality, infection rate, antibiotic use, and 
days with fever up to day 7; shift analysis of the mRS; Barthel 
Index (BI) at day 90; and mRS and BI at day 180.
Statistical analyses and Sample  
Size Calculation
The aim of this study was to estimate the probability of an accept-
able outcome (mRS 0–4) at day 90, as well as the proportion of 
patients receiving antibiotic treatment for both the new regime 
(PCT group) and the standard treatment (control group) based 
on the intention-to-treat (ITT) population. Two scenarios were 
considered a positive result: (a) improved outcome in the PCT 
arm, while the usage of antibiotics is equivalent, or (b) reduced 
usage of antibiotics in the PCT arm, while the outcome remains 
equivalent. A sample size of 70–90 per arm was considered to be 
sufficient to estimate each individual group proportion for both 
endpoints with a precision of <0.1 [95% confidence interval (CI)] 
and a power of 75–80% (13). To account for possible dropouts, 
a sample size of 100 per arm was targeted. In October 2013, we 
amended the protocol to increase the sample size to 230 due to a 
20% rate of missing outcomes at the 3-month assessment and 
without knowledge of any of the outcomes at this time.
Patients were included in the per-protocol (PP) analysis, if 
they were treated according to the study protocol (which allowed 
overruling of the PCT guidance) (13), whereas the PPadherence analy-
sis only included patients who had been treated strictly according 
to PCT guidance. Statistical associations were analyzed using chi-
square or Fisher’s exact tests (for less than 5 in one category) for 
categorical variables. Group comparisons of continuous variables 
were analyzed by Wilcoxon rank-sum test (skewed distribution) 
or t-test (symmetrical distribution). Statistical significance was 
set at p < 0.05. The mRS was additionally analyzed as a continu-
ous instead of a categorical variable to include the full range of 
this variable and to avoid loss of information by dichotomization. 
The shift analysis was performed by a randomization approach 
according to Howard et al. (15), to achieve a more detailed com-
parison of the frequency distributions of mRS 3-month outcomes 
between PCT and standard groups. This analysis was performed 
for the entire ITT patient population, as well as for patient strata 
with either initial mRS 4 or mRS 5 to account for imbalance in 
the initial stroke severity between the groups.
rESUlTS
Between February 2011 and April 2014, 235 patients were 
enrolled and randomly assigned to the 2 study groups. Eight 
TaBlE 1 | Baseline characteristics by analysis group (iTT and PP).
Variable level iTT PP
PCT (N = 112) STD (N = 115) p Value PCT (N = 104) STD (N = 102) p Value
Gender, N (%) Male 52 (46) 49 (43) 0.66 50 (48) 44 (43) 0.57
Female 60 (54) 66 (57) 54 (52) 58 (57)
Age (years), mean (SD) 76.2 (11.5) 76.1 (11.3) 0.91 76.1 (11.8) 75.3 (11.6) 0.63
Total NIHSS initial visit, median (IQR) 14 (12–18) 15 (12–19) 0.49 14 (11.75–17) 14 (12–18) 0.53
Barthel Index at day 7, median (IQR) 15 (0–40) 10 (0–33.75) 0.21 15 (0–40) 10 (0–35) 0.24
mRS before study, N (%) 0 61 (55) 72 (64) 0.46 59 (57) 66 (66) 0.42
1 17 (15) 18 (16) 15 (14) 15 (15)
2 11 (10) 8 (7) 10 (10) 8 (8)
3 21 (19) 13 (12) 18 (17) 11 (11)
4 2 (2) 1 (1) 2 (2) 0 (0)
mRS at initial visit, N (%) ≤4 44 (39) 31 (27) 0.067 42 (40) 28 (28) 0.07
5 68 (61) 84 (73) 62 (60) 74 (73)
mRS at day 7, N (%) 1 3 (3) 0 (0) 0.68 3 (3) 0 (0) 0.60
2 5 (5) 4 (4) 5 (5) 4 (4)
3 9 (8) 8 (7) 8 (8) 8 (8)
4 33 (30) 38 (34) 33 (32) 36 (35)
5 54 (50) 57 (50) 52 (51) 54 (53)
6 5 (5) 6 (5) 1 (1) 0 (0)
Diabetes mellitus, N (%) Yes 24 (22) 38 (34) 0.08 22 (22) 36 (36) 0.048
No 84 (78) 75 (66) 78 (78) 65 (64)
Atrial fibrillation, N (%) Yes 55 (51) 59 (53) 0.96 52 (53) 51 (51) 0.94
No 52 (49) 53 (47) 47 (48) 49 (49)
History of stroke, N (%) Yes 31 (29) 23 (21) 0.26 27 (27) 21 (21) 0.45
No 77 (71) 86 (79) 73 (73) 77 (79)
Hypertension, N (%) Yes 94 (85) 99 (87) 0.79 87 (85) 89 (87) 0.71
No 17 (15) 15 (13) 16 (16) 13 (13)
Hypercholesterolemia, N (%) Yes 54 (51) 61 (55) 0.70 51 (52) 54 (54) 0.95
No 52 (49) 51 (46) 47 (48) 47 (47)
Coronary heart disease, N (%) Yes 22 (22) 30 (28) 0.40 22 (24) 27 (28) 0.62
No 78 (78) 77 (72) 70 (76) 69 (72)
COPD, N (%) Yes 19 (19) 6 (6) 0.007 19 (20) 5 (5) 0.005
No 83 (81) 100 (94) 75 (80) 89 (95)
Smoker, N (%) Yes 18 (19) 13 (13) 0.30 18 (21) 13 (14) 0.33
No 76 (81) 89 (87) 68 (79) 78 (86)
Thrombolysis, N (%) Yes 61 (54) 54 (47) 0.26 58 (56) 48 (47) 0.21
No 51 (46) 61 (53) 46 (44) 54 (53)
COPD, chronic obstructive pulmonary disease; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; ITT, intention to treat;  
PP, per protocol; PCT, procalcitonin group; STD, control group.
p Values are calculated by Fisher’s test, chi-square test, Wilcoxon test, or t-test as appropriate.
TaBlE 2 | Serious adverse event reports per study group for intention-to-
treat analysis (N = 227).
PCT (N = 112), N (%) STD (N = 115), N (%)
Pneumonia 33 (29) 31 (27)
Death 4 (4) 6 (5)
Pulmonary embolism 1 (1) 2 (2)
Sepsis 2 (2) 1 (1)
Intracerebral hemorrhage 2 (2) 0 (0)
Heart failure 1 (1) 2 (2)
Acute myocardial infarction 2 (2) 1 (1)
Reinfarction 0 (0) 3 (3)
PCT, procalcitonin group; STD, control group.
Data are based on day 1–7 of the study.
TaBlE 3 | mrS scores at the 3-month follow-up assessment.
Group mrS ≤ 4,  
n (%)
Odds ratio 
PCT vs. 
STD
95% Ci p Value
lower 
Ci
Higher 
Ci
ITT 
(N = 227)
PCT 52 (52) 0.79 0.45 1.35 0.475
STD 56 (58)
PP 
(N = 206)
PCT 50 (54) 0.71 0.39 1.28 0.288
STD 54 (63)
PP adh. 
(N = 170)
PCT 37 (58) 0.81 0.42 1.57 0.613
STD 54 (63)
ITT, intention to treat; PP, per protocol; PP.adh., per protocol adherence; PCT, 
procalcitonin group; STD, control group; CI, confidence interval; mRS, modified  
Rankin Scale.
p Values are calculated by Fisher’s exact test.
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patients withdrew consent after study enrollment but before the 
first study-related assessment was performed, resulting in a total 
of 227 patients for the ITT analysis (112 in the PCT group and 
115 in the control group). Two hundred six patients (104 in the 
PCT group and 102 in the control group) were included in the 
PP analysis. Adherence to PCT guidance was 65%, leaving 170 
patients for the PPadherence analysis (68 in the PCT group and 102 
in the control group). Physicians overruled PCT guidance either 
by treating with antibiotics despite PCT values below the cutoff 
FiGUrE 2 | Distribution of modified rankin Scale (mrS) scores 3 months after stroke onset. Percentage of respective scores in the guidance [procalcitonin 
(PCT)] group and control group (STD) in the intention-to-treat analysis. Scores on the scale range from 0 to 6, with 0 indicating no symptoms and 6 indicating death.
TaBlE 4 | Shift analysis of mrS scores at the 3-month follow-up assessment.
Shift for mrS V90 Median (iQr) p Value randomization approacha
PCT STD Proportion 
better (%)
Proportion 
worse (%)
Proportion 
same (%)
ratio (better vs. 
worse)
ITT All (no adjustment) 4 (3.0–6.0) 4 (3.0–6.0) 0.452 37 42 21 0.88
mRS V0 = 4 4 (2.5–3.0) 3 (3.0–4.5) 0.477 39 42 19 0.92
mRS V0 = 5 5 (4.0–6.0) 4 (4.0–6.0) 0.840 30 45 25 0.66
PP All (no adjustment) 4 (3.0–5.0) 4 (3.0–5.0) 0.563 37 43 20 0.86
mRS V0 = 4 4 (2.3–4.8) 3 (3.0–4.0) 0.511 38 43 19 0.89
mRS V0 = 5 5 (4.0–6.0) 4 (4.0–5.0) 0.902 29 48 23 0.62
PP adh. All (no adjustment) 4 (3.0–5.0) 4 (3.0–5.0) 0.330 40 40 20 0.99
mRS V0 = 4 3 (2.0–4.0) 3 (3.0–4.0) 0.153 47 33 21 1.45
mRS V0 = 5 5 (4.0–6.0) 4 (4.0–5.0) 0.873 29 48 23 0.62
ITT, intention to treat; PP, per protocol; PP.adh., per protocol adherence; mRS, modified Rankin Scale; PCT, procalcitonin group; STD, control group.
Results were analyzed stratified by baseline mRS (mRS V0 = 4, mRS V0 = 5) because this variable was distributed differently in both study groups.
aBased on the study by Howard et al. (15).
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(28% of patients in the PCT group) or by not treating patients 
with antibiotics although PCT values were above the cutoff 
value indicative of an underlying bacterial infection (37% of 
patients in the PCT group). Eight centers included more than 
10 patients into this study. Among these, the adherence to 
PCT guidance ranged between 33 and 100% (mean 60%). The 
3-month follow-up was completed by 197 (87%) patients from 
ITT group. The rate of 3-month follow-ups was 84% (n = 97) in 
the control group and 89% (n = 100) in the PCT group (Figure 1; 
p = 0.28).
The study groups did not differ regarding baseline demo-
graphic and clinical characteristics, except for a higher rate of 
chronic obstructive pulmonary disease (COPD) in the PCT 
group and a higher rate of diabetes mellitus in the control group 
(Table 1). There was a trend toward higher baseline mRS scores 
at the time of the initial study visit in the control group (p = 0.067 
in ITT; p = 0.070 in PP).
Apart from SAP, the frequency of SAEs was low. There was 
no significant difference in the frequency of SAEs between the 
study groups (Table 2).
Procalcitonin-based antibiotic therapy guidance was not 
associated with an increased proportion of acceptable outcome 
(mRS ≤  4) at 3  months, neither in the ITT (OR 0.79, 95% CI 
0.45–1.39, p = 0.47) nor in the PP (OR 0.71, 95% CI 0.39–1.48, 
p  =  0.29) or PPadherence analyses (OR 0.81, 95% CI 0.42–1.57, 
p = 0.61, Table 3). The mRS distribution 3 months after stroke 
onset in both study groups is shown in Figure 2. In secondary 
endpoint analyses, outcome at 6 months was similar between both 
groups (p = 0.66 for ITT population). A shift analysis of the mRS 
(15) also revealed no significant differences between the groups. 
In all shift analysis scenarios considered, the proportion of better 
outcome was lower than the proportion of worse outcome for 
patients of the PCT group when compared with patients of the 
control group (Table  4). The proportion of a BI of ≥60 in the 
3-month follow-up as a measure for favorable outcome was simi-
lar in the PCT and control groups (median BI, ITT: 62.5 in PCT 
group vs. 55 in control group, p = 0.415; PP: 62.5 in PCT group vs. 
55 in control group, p = 0.542). Mortality rates (Figure 3) were 
not significantly different between groups during 3  months 
(PCT group vs. control group—ITT: OR 1.20, 95% CI 0.65–2.24; 
FiGUrE 3 | Three-month survival in the intention-to-treat population. PCT, PCT group; STD, control group. In the PCT group, 81 of 106 patients survived 
90 days after stroke onset, whereas in the STD group, 89 of 108 patients survived.
TaBlE 5 | infections and antibiotic treatment per study group for 
intention-to-treat analysis (N = 227).
PCT (N = 112), 
N (%)
STD (N = 115), 
N (%)
p Value
Pneumonia or sepsis 33 (29) 31 (27) 0.79
Urinary tract infection only 8 (7) 11 (10) 0.68
Antibiotic treatment 70 (63) 52 (45) 0.01
PCT, procalcitonin group; STD, control group. Data are based on day 1–7.
p Values are calculated by chi-square test.
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PP: OR 1.28, 95% CI 0.64–2.58) and 6 months of follow-up (PCT 
vs. control group—ITT: OR 1.34, 95% CI 0.75–2.41; PP: OR 1.42, 
95% CI 0.75–2.6).
Within the first week after stroke onset, the presence of SAP 
or sepsis (with or without further infections) was diagnosed in 
64 (28%) patients. Urinary tract infection (UTI) without SAP 
was diagnosed in 19 (8%) patients. Infection rates within the first 
7 days after stroke onset were similar in both study groups (SAP 
29% in PCT group vs. 27% in STD group; UTI 7% in PCT group 
vs. 10% in STD group; Table 5).The median number of days with 
fever tended to be higher in controls (2 days in control group vs. 
1 day in PCT group, p = 0.055; Figure 4A).
In the ITT analysis, antibiotic treatment was more frequent 
in the PCT compared to the standard group. Sixty-three percent 
of patients in the PCT group received antibiotic treatment, 
compared to 45% of patients in the control group (Table  5). 
The total number of days treated with (any) antibiotics within 
the first week after stroke onset was 362 [median 3, interquartile 
range (IQR) 0–6] in the PCT group (n = 112) compared to 250 
(median 0, IQR 0–5) in the control group (n = 115) (p = 0.004; 
Figure 4B). A post hoc analysis of the use of antibiotic substances 
between day 1 and day 7 after stroke onset showed significant 
differences between the study groups (Table 6; p = 0.0004).
In contrast to patients with UTIs, SAP patients have a mortal-
ity rate that was twice as high as in patients without SAP within 
3 months of follow-up (Table 7; p = 0.0055). Pneumonia rates 
following the acute course of stroke (3-month follow-up: 6% 
PCT vs. 7% STD, 6-months follow-up: 8% PCT vs. 9% STD) and 
rehospitalization rates (3-month follow-up: 10% PCT vs. 7% STD, 
6-months follow-up: 14% PCT vs. 10% STD) were comparable in 
both groups.
A post hoc analysis of all PCT values in the ITT population 
demonstrated a significant increase on the first day of infection 
in patients with pneumonia and sepsis compared to patients 
with UTIs or without infections [median (IQR): no infection 
0.042 (0.026–0.068), UTI only 0.044 (0.029–0.072), and pneu-
monia/sepsis 0.076 (0.043–0.175); Figure  5A]. PCT values 
were significantly higher in patients with SAP or sepsis (±UTI) 
between day 1 and 7 following stroke onset compared to patients 
without infections (Figure 5B).
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FiGUrE 4 | Days with fever and antibiotic treatment within the first 7 days after stroke onset. Proportion of patients with 0, 1, 2, 3, 4, 5, 6, or 7 days of  
(a) fever defined by body temperature ≥37.5°C and (B) antibiotic treatment in the guidance [procalcitonin (PCT)] group and control group (STD) of the intention- 
to-treat (ITT) population.
TaBlE 6 | Treatment days with different antibiotic classes per study group.
Group antibiotic class
Penicillin Cephalosporin Quinolone Macrolide lincosamide Others Sum
PCT, N (%) 174 (35) 148 (30) 17 (3) 34 (7) 16 (3) 109 (22) 498 (100)
STD, N (%) 107 (30) 97 (27) 32 (9) 24 (7) 28 (8) 68 (19) 356 (100)
PCT, procalcitonin group; STD, control group.
Days with antibiotic treatment between visit 1 and 7.
TaBlE 7 | Three-month mortality stratified by stroke-associated 
pneumonia and treatment group.
 Pneumonia or sepsis no pneumonia and no sepsis
PCT 39% (13 of 33) 20% (15 of 75)
STD 36% (11 of 31) 18% (14 of 80)
Sum 38% (24 of 64) 19% (29 of 155)
p Value 0.95 0.69
PCT, procalcitonin group; STD, control group.
% mortality at 3 months (# dead of N). p Values are calculated by chi-square test.
DiSCUSSiOn
PCT ultrasensitive-guided antibiotic treatment of bacterial 
pneumonia in acute stroke patients is a safe treatment strategy. 
However, our study failed to demonstrate an improvement of 
stroke outcome for this treatment approach. Moreover, SAP and 
mortality rates were similar in both study groups.
Only recently, two large randomized controlled phase III 
trials demonstrated neither an improvement of stroke outcome 
nor a significant reduction of SAP rate by preventive antibiotic 
therapy (5, 6). Both trials reported a significant reduction in UTIs, 
which are known to be unrelated to poststroke outcome (7).
In our study, PCTus guidance did not affect the frequency of 
clinical diagnosis of SAP, since infection rates were similar in both 
treatment groups. However, the usage of antibiotics (measured in 
days with antibiotic treatment) was higher in the PCT compared 
to the control group. Days with fever tended to be reduced by 
PCTus-guided treatment, which is important to note, since fever 
is a negative prognostic factor for stroke outcome (16).
Procalcitonin testing has also been shown to improve diag-
nostic accuracy for SAP in previous observational studies, where 
it was shown to improve specificity in case of clinical suspicion 
of SAP (12). Accordingly, a post  hoc analysis of PCT values in 
our study demonstrated a significant increase of PCT in patients 
with SAP and sepsis on the first day of infection, compared to 
patients with UTIs or without infections. Although there is a 
frequent request for biomarkers as a criterion for diagnosing SAP 
(9, 17), the adherence to the PCT guidance was surprisingly low. 
In the PCT group, overruling of the PCT guidance by the treating 
physician was allowed due to ethical concerns. Strict guidance to 
PCT was followed in only 65% of the patients, with considerable 
differences between the centers. This may be considered a prob-
lem of trust by some physicians in this new treatment approach 
under testing and may have impacted to some degree the trial 
outcome.
In clinical routine, physicians diagnose SAP based on clinical 
criteria, mainly fever, and are influenced by risk factors for SAP, 
e.g., stroke severity, while biomarkers are only used as additional 
diagnostic information (17). Overall, clinicians tend to overdi-
agnose SAP (7), reinforcing the need for operational diagnostic 
SAP criteria (18, 19). Although robust data are missing, it appears 
likely that overdiagnosing might cause an overtreatment of patients 
after stroke. In our trial, patients in the control group were treated 
according to the current standards of therapy, where manage ment 
of infections is based on the clinical judgment of the treating 
physicians. Current European and US stroke guidelines strictly 
recommend early antibiotic treatment of poststroke infections 
but advise against their prophylactic use (8). However, while 36% 
of patients in PCT group and 37% of patients in control group 
were diagnosed with a poststroke infection, 63% of patients in 
the PCT group received antibiotic treatment, compared to 45% in 
the standard group. With a low threshold for antibiotic treatment 
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FiGUrE 5 | Procalcitonin (PCT) in different types of poststroke infections. (a) PCT values of the first day of urinary tract infection (UTI) only or stroke-
associated pneumonia (SAP) were compared to all PCT values obtained within the first 7 days after stroke onset from patients before infection was diagnosed or 
without any infection. The red line indicates the cut-off for the PCT concentration of 0.05 ng/ml. (B) PCT values of the first 7 days were compared between patients 
diagnosed for UTI only, SAP, and for patients without any diagnosed infection. Analyses are based on the intention-to-treat group.
after stroke in clinical routine, preventive treatment strategies 
might not be able to add benefits to patients’ care.
The occurrence of SAP was associated with a twofold increase 
of mortality within 3  months of follow-up, which is in line 
with previous studies (20). As there is no evidence of improved 
outcome by preventing infections so far, there is an ongoing dis-
cussion whether a causal relationship between SAP and outcome 
after stroke exists (5, 21). Caution should be exercised not to 
label SAP as mere marker of detrimental outcome prematurely, 
as data available so far do not allow excluding a causal relation-
ship. Although patients in both PASS and STROKE-INF received 
antibiotics that are commonly used for pneumonia treatment in 
a prophylactic manner, the incidence of SAP remained unchanged 
compared to patients treated with standard stroke unit care only. 
This might be due to late initiation of prophylactic treatment in 
these trials or inappropriate choice of antibiotics (17); however, 
SAP might also harbor a greater non-infective inflammatory 
component than previously thought, which might not be pre-
vented by antibiotic treatment alone (7). As a stroke-induced 
immunosuppressed state is an important risk factor for SAP, the 
use of targeted immune modulators might be a promising new 
treatment approach (22).
Our study has several limitations. Our study has small base-
line imbalances for stroke severity in favor of the control and 
for COPD in favor of the PCT group. More importantly, the low 
adherence to the PCT guidance might have caused an under-
estimation of the effects of PCTus-guided antibiotic treatment. 
In addition, the number of included patients was rather small 
in comparison with the recent phase III studies on preventive 
antibiotics. However, we only included severely affected stroke 
patients who are known to have a higher risk of infections, and 
the overall infection rate in our trial was 37%, which is higher 
than in the previously reported trials (5, 6). In addition, variations 
in antibiotic substances and doses might have influenced 
our results. The high rate of antibiotic treatment in the control 
group might have confounded benefits of PCTus-guided antibi-
otic treatment.
In conclusion, our results do not support the use of PCTus-
guided antibiotic treatment of SAP to improve long-term 
outcome after stroke. However, a post hoc analysis of our data 
affirms that PCTus is a useful biomarker for diagnosis of SAP. The 
utility of PCTus as a biomarker for the diagnostic setup of SAP 
needs to be addressed in further trials, e.g., a cutoff level with 
high positive and negative predictive values needs to be 
established. Moreover, subsequent trials identifying biomarker 
patterns for prediction of SAP at stroke onset [among others 
PCTus, copeptin (23)] might provide the rational basis for 
biomarker-guided anti-infective immunomodulatory treatment 
already starting in the hyperacute phase of stroke in patients at 
risk for SAP.
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